NEW YORK, Oct. 11 – Luminex said on Thursday that a surprising surge in sales during the third-quarter will help the company report greater-than-expected revenues and a leaner loss than Wall Street had forecast for the period.
The Austin, Tex.-based bead-array developer said in a statement that revenues for the quarter ended Sept. 30 would be about $6.2 million, exceeding the $6.1 million offered by an analysts’ consensus estimate.
Luminex also plans to announce a loss of 13 cents per share, compared with the loss of 18 cents forecast by an analyst consensus estimate.
The company, which plans to report its results after the market closes on Oct. 18, had been expected to lose between 16 cents and 19 cents per share in the third quarter, according to a survey of five analysts by Thomson Financial/First Call. Their consensus forecast was a loss of 18 cents.
Luminex is known chiefly for its LabMap technology, which beside genomics and proteomics research is used in pharmaceutical drug discovery, clinical diagnostics, and biomedical research.
Last month, the American Society of Histocompatibility and Immunogenetics cleared Orchid Biosciences to perform human leukocyte antigen testing using the LabMap platform. Orchid becomes the first firm to be certified to perform the testing with the LabMap technology.
Orchid said on Sept. 19 it plans to use the HLA testing to determine the potential for tissue or organ compatibility in single-sample testing and donor recruitment drives. The platform may also help determine whether a patient can accept donations of certain types of stem cells.